Vaxcyte, Inc. (NASDAQ:PCVX) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of Vaxcyte, Inc. (NASDAQ:PCVX) have been given a consensus recommendation of “Moderate Buy” by the eight analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $106.25.

PCVX has been the topic of several research reports. The Goldman Sachs Group initiated coverage on Vaxcyte in a research report on Friday, September 12th. They set a “neutral” rating and a $38.00 price objective on the stock. Cowen reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Thursday, August 7th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Tuesday, October 14th.

Institutional Trading of Vaxcyte

Several large investors have recently bought and sold shares of the company. RA Capital Management L.P. boosted its position in Vaxcyte by 40.3% during the 1st quarter. RA Capital Management L.P. now owns 12,189,149 shares of the company’s stock valued at $460,262,000 after acquiring an additional 3,499,959 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Vaxcyte by 0.7% during the first quarter. Vanguard Group Inc. now owns 12,043,805 shares of the company’s stock valued at $454,774,000 after purchasing an additional 82,118 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Vaxcyte by 44.4% during the first quarter. Wellington Management Group LLP now owns 6,416,930 shares of the company’s stock valued at $242,303,000 after purchasing an additional 1,972,918 shares during the last quarter. State Street Corp lifted its holdings in shares of Vaxcyte by 12.1% during the second quarter. State Street Corp now owns 4,942,235 shares of the company’s stock valued at $160,672,000 after purchasing an additional 534,552 shares during the last quarter. Finally, Westfield Capital Management Co. LP lifted its holdings in shares of Vaxcyte by 42.4% during the second quarter. Westfield Capital Management Co. LP now owns 3,068,898 shares of the company’s stock valued at $99,770,000 after purchasing an additional 913,761 shares during the last quarter. 96.78% of the stock is owned by institutional investors.

Vaxcyte Trading Up 1.2%

Shares of NASDAQ PCVX opened at $45.28 on Friday. The firm has a market cap of $5.88 billion, a price-to-earnings ratio of -11.02 and a beta of 1.12. Vaxcyte has a 1-year low of $27.66 and a 1-year high of $116.00. The stock has a fifty day simple moving average of $36.99 and a two-hundred day simple moving average of $34.63.

Vaxcyte (NASDAQ:PCVX) last posted its earnings results on Wednesday, August 6th. The company reported ($1.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same period in the prior year, the company earned ($1.10) earnings per share. Analysts forecast that Vaxcyte will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.